Healthcare Industry News: Protonix
News Release - January 30, 2008
Prasco to Distribute Wyeth's Own Generic Versions of Protonix(R) Delayed-Release TabletsCINCINNATI--(HSMN NewsFeed)--Prasco announced today that, pursuant to an agreement it entered into with the ESI Lederle Division of Wyeth (“ESI”), it is shipping the generic version of Protonix® (Pantoprazole Sodium) Delayed-Release Tablets being offered for sale by ESI. Prasco, as ESI’s agent and on ESI’s behalf, will solicit orders for and distribute the 20 mg and 40 mg formulations of Pantoprazole Sodium Delayed-Release (DR) Tablets to all trade classes in the U.S. under the ESI Lederle label. Pantoprazole Sodium DR Tablets are AB-rated, therapeutically equivalent and substitutable for the brand Protonix Delayed-Release (DR) Tablets.
“We are extremely pleased to have established this agreement with Wyeth, a global leader in the pharmaceutical industry,” said Prasco Chief Executive Officer E. Thomas Arington. “Pantoprazole Sodium DR Tablets are identical to Protonix DR Tablets, providing the consuming marketplace the benefits of competitive balance and brand-quality at generic prices,” stated Arington.
Protonix DR Tablets had reported sales of $2.5 billion dollars in the United States, with over 19 million prescriptions filled for the twelve months ended November 30, 2007, based on IMS sales data. Protonix is a registered trademark of Wyeth Pharmaceuticals, Inc.
Pantoprazole Sodium DR Tablets are the latest products by Prasco. Prasco’s mission is to provide both quality products and significant cost-savings to the marketplace. Prasco’s goal is to provide patients with an identical brand experience through generic products manufactured by brand companies and marketed as generics. The Prasco product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.
The company operates its administrative office and warehouse facilities from Cincinnati, OH. Go to www.prasco.com for more information about the company.
Source: Prasco Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.